At a glance
ClinicalIndex Comparison RecordPhase 2Active· 12 enrolled
Drug / intervention
Pembrolizumab +1 moredrug
Likely dose
Not stated in record
Key inclusion· 7
- ✓Histologically confirmed metastatic uveal melanoma
- ✓Age ≥18 years
- ✓Prior hepatic directed therapy for metastatic uveal melanoma permitted
- ✓Measurable disease per RECIST 1.1
Key exclusion· 17
- ✕Prior anti-PD-1, anti-PD-L1, or anti-PD-L2 monotherapy for uveal melanoma
- ✕Prior PARP inhibitor therapy
- ✕Prior systemic anti-cancer therapy within 4 weeks or 5 half-lives
- ✕Radiotherapy within 2 weeks of study start
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted Sep 1, 2022·Updated Jun 22, 2026
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab and Olaparib for Uveal Melanoma and Ocular Melanoma. Active but no longer recruiting, targeting 12 participants across 1 site.
Detailed Summary
This is a prospective phase II multi-center trial of the combination of the PARP inhibitor olaparib with the immune checkpoint inhibitor pembrolizumab in advanced uveal melanoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUveal Melanoma, Ocular Melanoma
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2Active
202320242025202620272028
First PostedSep 2022
Enrollment StartOct 2022
Primary CompletionJul 2026
TodayJul 2026
Study CompletionDec 2027
First PostedSep 1, 2022
Enrollment StartOct 11, 2022
Primary CompletionJul 1, 2026
Study CompletionDec 1, 2027
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 3.8 years ago
Interventions
Pembrolizumabdrug
Pembrolizumab Day 1 of each 21 day (3 week) cycle
Olaparibdrug
Olaparib by mouth days 1-21 of each 21 day (3 week) cycle